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PBMCs from patients with AD who were sensitized to Mala s 13
with lactic acid to remove surface-bound IgE.E3,E4 By using this
treatment, surface levels of IgE on monocytes were reduced (Fig
1,D), and IL-10 secretion was significantly increased after Mala s
13 stimulation but not after hTrx stimulation (Fig 1, E). In
contrast, IL-13 secretion could be reduced after lactic acid treat-
ment followed by hTrx stimulation but not by Mala s 13 stimula-
tion (Fig 1, E). An explanation for these discrepancies might be
the small fraction of Mala s 13– and hTrx-specific IgE in relation
to the patient’s total serum IgE levels. In fact, the increase in IL-10
levels after IgE stripping and stimulation with Mala s 13 corre-
lated with the Malassezia species–specific IgE/total IgE ratio
(Spearman r 5 0.536, P 5 .048). In turn, this can be explained
by the correlation of monocyte surface levels of FcεRI with total
serum IgE levels.6
Our findings are in contrast to those of previous reports showing
an increased IL-10 secretion of FcεRI-activated monocytes.7,8
This might be due to differences in the experimental setup, such
as the use of monoclonal IgE and anti-IgE for receptor cross-
linking compared with our assay by using 1 distinct allergen, as
well as due to different cell-culture conditions and the time point
of analysis. Using anti-IgE stimulation, we could also upregulate
IL-10 in PMBCs from patients with AD who were sensitized to
Malassezia species (see Fig E3 in this article’s Online
Repository at www.jacionline.org). Therefore this discrepancy be-
tween massive IgE receptor cross-linking with anti-IgE and the
potentially weaker cross-linking resulting from application of
native allergens should be considered in future studies.
The major findings of this study are (1) an IgE-dependent
upregulation of the TH2 cytokine IL-13 by hTrx and (2) an
impaired upregulation of IL-10 by hTrx in patients with AD
who were sensitized to Mala s 13 and hTrx. IL-10 promotes the
development of regulatory dendritic cells and T cells and there-
fore tolerance, and it is involved in a number of processes
involved in the downregulation of a local inflammatory response.9
The relative lack of antigen-specific IL-10 secretion in PBMCs
from patients with AD whowere sensitized toMalassezia species
might contribute to the perpetuation of the local cutaneous inflam-
mation in patients with AD and to further development of TH2-
and IgE-mediated immune responses. Moreover, specific sensiti-
zation against hTrx can directly be involved in disease exacerba-
tion in patients with AD because hTrx can be released from
dermal or epidermal cells and might then promote inflammatory
responses by activating specific T cells and cells expressing re-
ceptors for IgE.
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RAC2 loss-of-function mutation in 2 siblings
with characteristics of common variable
immunodeficiency
To the Editor:
Common variable immunodeficiency (CVID) represents a
heterogeneous group of disorders with variable immunologic
and clinical phenotypic features, including hypogammaglobulin-
emia, recurrent infections, and autoimmunity.1 Over the past
decades, a number of genetic defects have been identified that
are associated with CVID. However, these alterations only
account for the cause of a minority of CVID cases (<15%).1 In
this article we present a novel genetic defect in the Ras-related
C3 botulinum toxin substrate 2 (RAC2) gene in 2 siblings
previously given a diagnosis of CVID.
TABLE I. Laboratory and immunologic data of 2 patients with
RAC2 deficiency
Laboratory test Proband Sibling Reference values*
Complete blood count Age 1 y Age 7 y
WBC/mm3 9,200 7,800 4,000-11,000
Neutrophils (%) 62 66 20-70 (for age 1 y)
35-80 (for age 7 y)
Lymphocytes (%) 27Y 25Y 45-75 (for age 1 y)
30-55 (for age 7 y)
CD31 (%) 60 62 30-78
CD41 (%) 30 25 22-58
CD81 (%) 33 35 10-37
CD41/CD81 ratio 0.9Y 0.7Y 1-4
CD191 (%) 2.5Y 8.5 3-14
Serum complement
factors
Age 1 y Age 7 y
C3 (mg/dL) 79Y 110 83-177
C4 (mg/dL) 27 20 15-45
Neutrophil analyses Age 7 y Age 28 y
CD181 (%) 70 NA 70-100
CD11a1 (%) 92[ NA 60-90
CD11b1 (%) 98[ NA 60-90
CD11c1 (%) 99[ NA 45-80
NBT test (%) 98 NA 95-100
Chemotaxis without
CF (mm)
NA 10Y 22-54
Chemotaxis with
CF (mm)
NA 45Y 77-125
Serum immunoglobulins Age 7 y Age 10 y
IgM (mg/dL) 30Y 28Y 40-230
IgG (mg/dL) 430Y 640Y 700-1600
IgA (mg/dL) 5Y 19Y 41-297 (for age 7 y)
51-297 (for age 10 y)
Vaccine antibodies Age 27 y
Antibody level before
Pneumovax 23 (U/mL)
NA 1Y 1.2-2
Antibody 3 wk after
Pneumovax 23 (U/mL)
NA 8Y 10-14
Antibody 1 y after
Pneumovax 23 (U/mL)
NA 8 6-9
Anti-tetanus (IU/mL) NA 1.56 >0.1
Anti-diphtheria (IU/mL) NA 0.4 >0.1
Autoantibodies and
thyroid markers
Age 7-16 y Age 10-16 y
ANA Negative Negative Negative
ANCA Negative Negative Negative
Anti-dsDNA Negative Negative Negative
Anti-TPO (IU/mL) 68[ 81[ 0-35
TSH (mU/L) 11.4[ 11.0[ 0.4-5.5
T3 (mg/dL) 30 33 25-36
T4 (nmol/L) 8 4Y 5-14
PTH (pg/mL) 194[ NA 15-65
GH (ng/mL) NA 1.3Y 10-40
Anti-IgA (U/mL) NA 2.0 1.5-2.9
Other tests Age 18 y Age 25 y
KRECs 2Y 8Y (85, 22)
TRECs 24Y 10Y (67, 23)
ANA, Anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody;
Anti-dsDNA, anti–double-stranded DNA antibody; Anti-TPO, anti-thyroperoxidase
antibody; CF, chemotactic factor; GH, growth hormone; KRECs, k-deleting
recombination excision circles; NA, not analyzed; NBT, nitroblue tetrazolium; PTH,
parathyroid hormone; TSH, thyroid-stimulating hormone.
*Reference: Age-appropriate reference range or value from healthy Iranian subjects.
The local hospital reference range is not stratified for age between 1 and 7 years.
Because of the lack of appropriate reference values for the adult population, results
of the TREC and KREC analyses were compared with those of 2 age-matched healthy
control subjects.
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 5
LETTERS TO THE EDITOR 1381The proband, a 21-year-old woman of Iranian descent born to
first-degree consanguineous parents, presented at 6 months of age
with recurrent pneumonia, followed by edema, proteinuria, and
membranous glomerulonephritis 6 months later, at which time
serum IgA was undetectable and her serum IgG level was
increased (see Table E1 in this article’s Online Repository at
www.jacionline.org). Based on the clinical presentation and an
increased anti–streptolysin O titer, a diagnosis of poststreptococ-
cal glomerulonephritis (PSGN) was made along with a tentative
diagnosis of selective IgA deficiency. At 1 year of age, the patient
had a normal percentage of CD31 T cells, a slightly reduced ratio
of CD41/CD81 T cells, and a decreased percentage of CD191 B
cells (Table I). Coagulation factor XI deficiency (activity <1%)
was diagnosed at 2 years of age. Dermatologic features developed
3 years later, including urticaria (induced by exposure to
sunlight), recurrent erythematous plaques, and food allergy
requiring corticosteroid therapy. Her neutrophil markers and
nitroblue tetrazolium test results were normal, but the IgG level
decreased to 430 mg/dL by 7 years of age. Thus a diagnosis of
CVID was made, and intravenous immunoglobulin treatment
was initiated (Table I and see Table E1). Other morbidities
in the following years included arthralgia, bronchiectasis,
hypothyroidism with anti-thyroperoxidase antibodies, and
hyperparathyroidism (Table I). Her PSGN progressed to
end-stage renal disease requiring renal transplantation. She died
as a result of graft rejection and possible cerebral hemorrhage
at the age of 21 years.
Her 28-year-old brother presented at 2 years of age with
recurrent sinopulmonary infections and failure to thrive. Urticaria
and sinusitis occurred at age 7 years, when selective IgA
deficiency was diagnosed with normal T- and B-cell
percentages in peripheral blood (Table I and see Table E1). At 8
years of age, he had pneumonia and subsequent PSGN (with an
increased anti–streptolysin O titer). Coagulation factor XI
deficiency was diagnosed at the age of 10 years. His IgM and
IgG serum levels were also reduced at this age (see Tables E1
and E2 in this article’s Online Repository at www.jacionline.
org), when a diagnosis of CVID was established and intravenous
immunoglobulin replacement was commenced. Between 10 and
16 years of age, he had submandibular reactive lymphadenopathy,
bronchiectasis, hypothyroidism with anti-thyroperoxidase
antibodies, and growth hormone deficiency (Table I). A recent
extended lymphocyte immunophenotyping showed severe
B-cell lymphopenia and abnormalities in T-cell subpopulations,
with reversed ratio of CD41/CD81T cells, decreased percentages
of naive CD41 and CD81 T cells, and reduced percentages of
regulatory T and recent thymic emigrant cells (see Table E3 in
this article’s Online Repository at www.jacionline.org).
A novel homozygous nonsense mutation in codon 56 (W56X)
was identified in the RAC2 gene in the proband by means of
whole-exome sequencing (WES) analysis. Mutations in F11,
encoding the coagulation factor XI, was excluded by using both
Sanger sequencing and WES data, with detailed information on
methods provided in the Methods section in this article’s Online
Repository at www.jacionline.org. All known causative gene
defects responsible for CVID were furthermore excluded in this
patient based on the WES data. Sanger sequencing confirmed
the homozygous RAC2 mutation in the proband, her brother,
and in a heterozygous form in their mother (Fig 1, A and B).
Western blot analysis was subsequently carried out on fibroblast
cells transfected with either a wild-type RAC2 plasmid or
FIG 1. A, Family pedigree (solid fill, homozygous; half fill, heterozygous carrier). The proband is indicated
by an arrow. The father’s sample was not available (NA). B, Sequence analysis of the RAC2 gene.
C, Detection of RAC2 expression by using Western blot analysis. Control, Fibroblast cells without
transfection.
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expression of RAC2 was completely absent in cells transfected
with the mutant identified in the patients (Fig 1, C).
The affected gene encodes RAC2, a hematopoietic-specific
member of the Rho family of guanosine triphosphatases (Rho
GTPase), which are crucial regulators of cell signaling and the
actin cytoskeleton. Because RAC2 deficiency has mainly been
associated with neutrophil dysfunction,2 neutrophils from the
proband were analyzed by using transmission electron
microscopy. The number of primary (azurophilic) and secondary
(specific) granules per square micrometer of cytoplasm
was significantly reduced in the proband (3.8 6 0.7/mm2 vs
5.9 6 1.3/mm2 in the control subject; P 5 2.3 3 1025, Student
t test). Furthermore, the shape of the secondary granules in the
proband was often more elongated or collapsed (Fig 2, C)
compared with that in the control subject (Fig 2,D). Cytoplasmic
inclusions were also more frequent in the proband (Fig 2, A). The
majority of inclusions were very dense and composed of a
multimembrane layer surrounded by a double membrane (Fig 2,
E) and were interpreted as autophagosomes. Morphologic
differences between the primary granules of the proband and
the control subject were not observed. Finally, a chemotactic
defect was observed in the neutrophils derived from the affected
brother (Table I).
To date, only de novo dominant negative mutations affecting
RAC2 (D57N) have been reported in 2 male infants.3-5 The first
case presented with a complex neutrophil dysfunction disease,
which was characterized by multiple and progressive soft-tissue
infections during the first few weeks of life, neutrophilia, and a
neutrophil chemotaxis defect.3,4 The second case was an
apparently healthy 2-week-old infant, who exhibited reduced
numbers of T-cell receptor excision circles (TRECs) in the
Wisconsin statewide newborn screening for T-cell lymphopenia.5
Further testing revealed leukocytosis, neutrophilia, CD41 T-cell
lymphopenia, and reduced serum IgA and IgM levels.5 He laterhad fever, omphalitis, and a paratracheal abscess, and neutrophil
chemotaxis was severely reduced.5 Both infants underwent
successful hematopoietic cell transplantations.4,5
For the first time, we describe a homozygous loss-of-function
RAC2 mutation in 2 patients with early-onset and progressive
hypogammaglobulinemia. As shown in Table E4 in this article’s
Online Repository at www.jacionline.org, the clinical and
laboratory findings of our patients differ from those of the
previously reported cases in many respects. Notably, our patients
did not present with severe clinical abnormalities in the neonatal
period associated with neutrophil dysfunction. This might be
explained by the fact that the previously reported cases involved
expression of a dominant negative protein, which affected the
GTPase activity not only of RAC2 but also of RAC1, the other
major RACGTPase expressed in human neutrophils.6,7 Neverthe-
less, neutrophils from our patients showed reduced chemotaxis
activity and, as revealed by using transmission electron
microscopic analysis, reduced numbers of neutrophil granules,
as well as morphologic changes of the secondary granules,
suggesting that neutrophil functions were still affected by the
RAC2 loss-of-function mutation. The antibody deficiency
observed in our patients supports an important role of RAC2 in
T- and B-cell development, as also suggested by murine studies,8
as well as some of the immunologic features observed in the
second infant carrying the D57N mutation.5 No Guthrie cards
were available from our patients that would allow a retrospective
analysis of TRECs. However, we did observe a reduced number of
TRECs and k-deleting recombination excision circles in the
patients’ peripheral blood compared with age-matched control
values, which, in line with the immunophenotyping data, might
suggest a decreased number of recent thymic emigrants and a
relative B-cell lymphopenia in both patients (Table I and see
Table E2). It is also of note that the antibody deficiency in our pa-
tients and the B-cell lymphopenia in the brother was progressive,
a feature that was not possible to evaluate in the previous cases
FIG 2. Transmission electron microscopic images of neutrophils. A, Proband: cytoplasmic inclusions
(arrow). B, Control subject: normal ultrastructure. C, Proband: fewer cytoplasmic granules, with most
secondary granules displaying an elongated or collapsed shape (arrow).D, Control subject: normal rounded
secondary granules (arrow). E, Proband: cytoplasmic inclusion, showing a dense multimembrane layered
structure (arrow) surrounded by a double membrane (arrowhead). F, Control subject: normal ultrastructure.
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at the age of 10 and 3 months, respectively. The urticaria in our
patients might be further related to the mast cell defects, as
observed inRac22/2 bonemarrow–derivedmast cells.9 However,
pinpointing a specific mechanism will require additional
investigations. Other phenotypes in our patients, such as multiple
hormone deficiencies, coagulation factor XI deficiency, and
PSGN, might not be attributable directly to the RAC2 mutationbecause expression of RAC2 is highly regulated and considered
hematopoietic specific. However, these phenotypes might be
secondary to the overall increased susceptibility to infections
(especially for PSGN) and/or autoimmunity in our patients
(evident by an increased serum level of B cell–activating factor
[BAFF] in the brother, data not shown). Thus the polyendocrino-
pathies, coagulopathy, and kidney disease observed might be part
of a syndromic entity related to RAC2 deficiency, as is the case in
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features.
Our patients illustrate that different types of mutations in a
given gene might be associated with vastly different clinical
phenotypes.10 Further investigation of the mutation identified in
this report might help to elucidate the function of this gene in
relation to this CVID-like but more complex immunodeficiency.
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Long-term remission after allogeneic hema-
topoietic stem cell transplantation in LPS-
responsive beige-like anchor (LRBA) deficiency
To the Editor:
LPS-responsive vesicle trafficking, beach and anchor
containing protein (LRBA) deficiency has been identified as a
primary immunodeficiency (PID) characterized by recurrent
infections associated with autoimmunity, such as inflammatory
bowel disease and autoimmune cytopenias (see Fig E1 in this ar-
ticle’s Online Repository at www.jacionline.org).1-3 Awide range
of immunosuppressive treatment measures have only induced
temporary relief in affected subjects. Although allogeneic
hematopoietic stem cell transplantation (HSCT) is the current
treatment for many forms of PIDs, HSCT is less established in
patients with autoimmune disease4,5 and has not yet been reported
in LRBA-deficient patients.
We studied a consanguineous family of Kurdish origin with a
systemic autoimmune disorder. Patient 1’s symptoms started at 2
years of age with immune thrombocytopenia (ITP; Fig 1, A).
Serum immunoglobulin concentrations were slightly increased,
and the cellular immunophenotype was normal (Table I and see
Table E1 in this article’s Online Repository at www.jacionline.
org). A lymph node biopsy performed because of generalized
lymphoproliferative disease (LPD) revealed a follicular
lymphatic hyperplasia with abundant (about 20% to 30%)
CD31 and CD42 and CD82 double-negative T lymphocytes
(DNT cells; Fig 1, C), suggesting an immune dysregulation,
lymphocytematuration, or apoptosis defect compatiblewith auto-
immune lymphoproliferative syndrome (ALPS).6,7 HSCT was
performed with the clinically healthy HLA-identical mother as
the donor (see the additional text in this article’s Online Reposi-
tory at www.jacionline.org), leading to complete remission with
persisting full donor chimerism and without signs of acute or
chronic graft-versus-host disease (GvHD). Four years after
HSCT, ITP relapsed but responded well to high-dose intravenous
immunoglobulin (IVIG) treatment. When romiplostim was
started, platelet counts normalized, and administration of
romiplostim (5 mg/kg, every 4 to 6 weeks) without further need
for immunosuppression or IVIG has led to sustained but
treatment-dependent remission.8
Patient 2, the now11-year-oldyounger sister of patient 1, became
symptomatic at 5 years of age (fulminant autoimmune hemolytic
anemia; Fig 1, B). Immunosuppression was started immediately
(corticosteroids, mycophenolate mofetil, and vincristine), leading
to a sustained remission (Fig 1, B). Rituximab was administered
METHODS
Clinical investigations
Informed consent for this study was obtained from the proband and her
relatives in accordance with the principles of the ethics committee of the
Tehran University of Medical Sciences.
Immunologic analyses
During follow-up, we performed different investigations according to
previously published methods, including measurement of complete blood
counts, serum immunoglobulin levels,E1 vaccine responses,E2 frequency
and/or function of regulatory T cells,E3 naive T cells,E4 and recent thymic
emigrant T cells.E4 A neutrophil chemotaxis assay was performed with
zymosan-activated serum, as previously described.E5
Serum BAFF measurement
The concentration of BAFF was assessed in stored serum samples by using
the Human BAFF (TNFSF13B) SimpleStep ELISA Kit (Abcam, Cambridge,
United Kingdom), according to the manufacturer’s instructions. Two healthy
control subjects were included. Statistical analysis (nonparametric analysis
[Kruskal-Wallis test]) was performed with Excel software.
Flow cytometric immunophenotyping
Venous blood was collected in EDTA tubes, and the samples were
processed within 36 hours. Antibody combinations were used for
polychromatic 8-color surface staining panels and optimized, as previously
published.E6
WES and validation by means of Sanger sequencing
The methods for DNA library preparation, read mapping, and variant
analysis and the analysis protocol for WES were performed, as described
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previously.E1 Sanger sequencing with specific primers (forward, GGAATGA
CATGGAGCTGGAC; reverse, AAGATGGGCACATTGAGGAC) was
performed to validate the potential disease-causing variant. PCR reactions
were performed, as described previously.E1 The purified PCR products were
sequenced by Macrogen Incorporated (Seoul, South Korea).
J ALLERGY CLIN IMMUNOL
MAY 2015
1384.e1 LETTERS TO THE EDITOR
TABLE E1. Immunoglobulin levels at different ages for patients with RAC2 deficiency
Age (y): 1 4 5 6 7 8 9 10 11 12 14 15 16 19 20
Proband
IgM (mg/dL) 180 40 95 110 30Y 42 182 NA NA NA 73 40 NA 50 NA
IgG (mg/dL) 1800[ 800 650Y 940 430Y* 380Y 600Y NA NA NA 780 790 NA 700 NA
IgA (mg/dL) 0Y 20 0Y 0Y 5Y 5Y 0Y NA NA NA 30Y 40Y NA 0Y NA
IgE (IU/mL) 9 NA NA NA <5 NA NA NA NA NA NA NA NA NA NA
Sibling
IgM (mg/dL) NA NA NA NA 105 190 17Y 28Y 36Y 19Y 0Y NA 21Y NA 58
IgG (mg/dL) NA NA NA NA 900 750 754 640Y* 520Y 600Y 99Y NA 542Y NA 130Y
IgA (mg/dL) NA NA NA NA 0Y 0Y 0Y 19Y 19Y 9Y 0Y NA 0Y NA 10Y
IgE (IU/mL) NA NA NA NA 5.3 NA NA NA NA NA <5 NA NA NA NA
Age-matched reference levels: 1-3 years—IgM, 55-210 mg/dL; IgG, 700-1600 mg/dL; IgA, 19-220 IU/mL; IgE, <100 IU/mL; 4-5 years—IgM, 40-230 mg/dL; IgG, 700-1600 mg/
dL; IgA, 48-345 mg/dL; 6-7 years—IgM, 40-230 mg/dL; IgG, 700-1600 mg/dL; IgA, 41-297 mg/dL; IgE, <100 IU/mL; 8-10 years—IgM, 40-230 mg/dL; IgG, 700-1600 mg/dL;
IgA, 51-297 mg/dL; 11-13 years—IgM, 40-230 mg/dL; IgG, 700-1600 mg/dL; IgA, 44-395 mg/dL; and >_14 years—IgM, 40-230 mg/dL; IgG, 700-1600 mg/dL; IgA, 70-400 mg/
dL; IgE, <100 IU/mL.
NA, Not analyzed.
*Treatment with intravenous immunoglobulin was started, with controlled kidney disorder and normal total protein and albumin levels.
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TABLE E2. IgG subclass levels in the 2 siblings with RAC2
deficiency
IgG subclass level (mg/dL)
Proband Sibling
Age 4 y Age 10 y
IgG1 (reference values) 405 (253-1019) 50Y (289-934)
IgG2 (reference values) 73 (54-435) <15Y (82-516)
IgG3 (reference values) 172[ (9-102) 12Y (20-103)
IgG4 (reference values) 15 (1-108) <5 (0.3-111)
Reference: Age-appropriate reference range from healthy Iranian subjects.
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TABLE E3. Lymphocyte subpopulations in the sibling with RAC2
deficiency
Laboratory test Sibling
Reference
range
Age at testing 26 y
CD41CD251FOXP31 regulatory T cells (%) 1.4Y 3.4-5.66
FOXP3 expression in PBMCs (%) 1.5Y 2.7-4.8
Regulatory T-cell suppressor capacity (%) 18Y 30-80
CD45RA1CD62L1CD41 naive T cells (%) 17.4Y 35-54
CD311CD45RA1CD62L1CD41 recent thymic
emigrant T cells (%)
26.4Y 32-50
Age at testing 28 y
NK cells (%) 11.7 3-22
CD191 cells (%) 0Y 6-23
CD31 cells (%) 87[ 56-84
CD41 cells (%) 26Y 31-52
CD81 cells (%) 57[ 18-35
CD4/CD8 cell ratio 0.5Y 1.0-3.6
NK T cells (%) 7.7 2.1-13.7
CD42CD82 T cells (%) 3.8 3-10.2
CD41CD82 T cells (%) 0.6 0.2-1.4
CD41CD381 T cells (%) 51 50-79
CD41HLA-DR1 T cells (%) 30[ 5-25
CD41CD381HLA-DR1 T cells (%) 10[ 2-6
CD81CD381 T cells (%) 55 33-80
CD81HLA-DR1 T cells (%) 66[ 5-25
CD81CD381HLA-DR1 T cells (%) 42[ 3-18
CCR71CD45RA1CD45RO2CD41 naive
T cells (%)
9.8Y 20.2-51.1
Effector memory CD41 T cells (%) 55.2 27.5-56.8
TH1 cells (%) 21.0 4.5-25.5
TH2 cells (%) 3.1 1.5-11.3
Central memory CD41 T cells (%) 10.2 7.7-17.5
T cells (naive/effector memory) 0.2Y 0.3-3.2
TH17 cells 39.4[ 15.1-37.0
Naive CD81 T cells (%) 1.8Y 28.4-66.7
Effector memory CD81 T cells (%) 67.0[ 11.5-42.6
Activated effector memory CD81 T cells (%) 1.9 0-22.4
Activated cytolytic effector CD81 T cells (%) 0.2 <5.9
Effector CD81 T cells (%) 15.9 7.4-24.6
Central memory CD81 T cells (%) 1.0 0.5-5.6
CD62L, CD62 ligand; FOXP3, Forkhead box protein 3; NK, natural killer.
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TABLE E4. Comparison of cases with RAC2 deficiency
Parameters Proband Sibling Colorado caseE7,E8 Wisconsin caseE9
Sex Female Male Male Male
Mutation W56X Hom W56X Hom D57N Het D57N Het
Effect of mutation Absent expression Absent expression Dominant negative Dominant negative
Age at onset of clinical
symptoms
6 mo 2 y 5 wk 26 d
Age at genetic diagnosis 19 y 23 y Within 10 mo of life Within 5 wk of life
Clinical features Recurrent pneumonia, hypogammaglobulinemia,
PSGN, factor XI deficiency, urticaria, allergy,
bronchiectasis, hypothyroidism,
hyperparathyroidism, ESRD
Recurrent sinopulmonary infections,
hypogammaglobulinemia, urticaria, PSGN,
factor XI deficiency, lymphadenopathy,
bronchiectasis, hypothyroidism,
GH deficiency
Recurrent perirectal abscess, umbilical
stump involution failure, infected
urachal cyst, failure of surgical
wound healing
Periumbilical erythema, macrocytic
anemia, paratracheal abscess
WBC/mm3 Normal Normal High High
Neutrophils (%) Normal Normal High High
Lymphocytes (%) Reduced Reduced Low-normal Reduced/normal
T cells (%) Normal Normal Low-normal Reduced/normal
B cells (%) Reduced Normal at age 7 y, reduced at age 28 y Low-normal Reduced/normal
IgM (mg/dL) Normal, then reduced Normal, then reduced Normal Reduced
IgG (mg/dL) Normal, then reduced Normal, then reduced Normal Normal
IgA (mg/dL) Reduced Reduced Normal Reduced
Neutrophil chemotaxis NA Moderately reduced Markedly reduced Markedly reduced
Oxidative burst* Normal NA Normal Normal
CD181 (%) Normal NA NA Normal
CD11a1 (%) Slightly increased NA NA NA
CD11b1 (%) Slightly increased NA Normal Normal
CD11c1 (%) Increased NA Normal NA
C3 (mg/dL) Slightly reduced Normal Reduced/normal NA
C4 (mg/dL) Normal Normal NA NA
KRECs Reduced Reduced NA NA
TRECs Reduced Reduced NA Reduced
Organisms isolated Streptococcus pneumoniae Streptococcus pneumoniae Escherichia coli, Enterococcus species
and Pseudomonas aeruginosa
Stenotrophamonas and Prevotella
species
Treatment Antibiotics, IVIG, immunosuppressive therapy,
levothyroxine, renal transplant
Antibiotics, IVIG, immunosuppressive
therapy, levothyroxine
Antibiotics, prednisolone, granulocyte
transfusion, BMT
Surgical debridement, abscess
drainage, granulocyte transfusion,
HSCT
Outcome Dead at 21 y from transplant rejection and
suspected cerebral hemorrhage
Alive Cured after BMT Cured after HSCT
All clinical immunologic details of the previously reported cases can be found in Ambruso et alE7 and Kurkchubasche et alE8 (the Colorado case) and Accetta et alE9 (Wisconsin case).
BMT, Allogeneic bone marrow transplantation; ESRD, end-stage renal disease; GH, growth hormone; Het, heterozygous; Hom, homozygous; HSCT, allogeneic cord blood hematopoietic stem cell transplantation; IVIG, intravenous
immunoglobulin; KRECs, k-deleting recombination excision circles; NA, not analyzed.
*Oxidative burst tested with phorbol myristate acetate.
Serum complement is mentioned to be reduced and normal in Kurkchubasche et alE8 and Accetta et al,E9 respectively.
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